$253.40+1.17%Close 13 Nov 2026 · Market value $37.59B
About Biogen
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis (collectively 45% of 2024 revenues); nusinersen (Spinraza) for the treatment of spinal muscular atrophy (16.2% of 2024 revenues); omaveloxolone (Skyclarys) for the treatment of Friedreich's ataxia (4.0% of 2024 revenues); tofersen (Qalsody) for the treatment of ALS; and dimethyl fumarate (Fumaderm) for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars (8.2% of 2024 revenues) and has collaborations with Genentech for several drugs (18.1% of 2024 revenues).
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000.
From Wikipedia, shared under CC BY-SA.
Company facts
| Ticker | BIIB · Nasdaq |
|---|
| Sector | Biotechnology |
|---|
| Industry | Biotechnology |
|---|
| Index | S&P 500 |
|---|
| Fiscal year ends | 31 December |
|---|
| Reporting currency | USD |
|---|
| CIK | 875045 |
|---|
Officers and directors
| Name | Role | Shares owned | Latest Form 4 |
|---|
| Christopher A. Viehbacher | President and CEO · Director | 111K · < 1% | Option exercise, 6 Feb 2026 |
|---|
| Susan H. Alexander | EVP Chief Legal Officer | 61.9K · < 1% | Option exercise, 6 Feb 2026 |
|---|
| Caroline D. Dorsa | Director | 31.0K · < 1% | Grant or award, 17 Jun 2025 |
|---|
| Michael R. McDonnell | EVP, Chief Financial Officer | 24.3K · < 1% | Option exercise, 10 Feb 2025 |
|---|
| Eric K. Rowinsky | Director | 24.3K · < 1% | Grant or award, 9 Jun 2026 |
|---|
| Nicole C. Murphy | Head of Pharm Ops and Tech | 19.7K · < 1% | Open-market purchase, 12 Feb 2026 |
|---|
| Stephen A. Sherwin | Director | 13.7K · < 1% | Grant or award, 9 Jun 2026 |
|---|
| Robin C. Kramer | Chief Financial Officer | 11.5K | Option exercise, 6 Feb 2026 |
|---|
| Jesus B. Mantas | Director | 9.8K · < 1% | Grant or award, 9 Jun 2026 |
|---|
| William A. Hawkins | Director | 8.9K · < 1% | Grant or award, 9 Jun 2026 |
|---|
| Priya A. Singhal | Head of Development | 8.0K · < 1% | Sale under a 10b5-1 plan, 9 Feb 2026 |
|---|
| Maria C. Freire | Director | 6.8K · < 1% | Grant or award, 9 Jun 2026 |
|---|
| Susan K. Langer | Director | 5.1K · < 1% | Grant or award, 9 Jun 2026 |
|---|
| Monish Patolawala | Director | 3.7K · < 1% | Grant or award, 9 Jun 2026 |
|---|
| Lloyd Minor | Director | 2.4K · < 1% | Sale under a 10b5-1 plan, 4 Aug 2026 |
|---|
| Menelas Pangalos | Director | 2.4K · < 1% | Option exercise, 9 Jun 2026 |
|---|
| Keeney Adam | Head of Corporate Development | — | Option exercise, 1 May 2026 |
|---|
| Godbout Sean | Chief Accounting Officer | — | Shares withheld for tax, 1 Apr 2026 |
|---|
| Izzar Rachid | Head of Global Product Strat. | — | Option exercise, 6 Feb 2026 |
|---|
| Grogan Jane | Head of Research | — | Shares withheld for tax, 6 Feb 2026 |
|---|
Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.
BIIB in the terminal
The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.